ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology

• ZEISS and Mindpeak to develop joint integrated mIF solution
• Addressing clinical and research applications in pathology
  

ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex Immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications.

Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements ZEISS's advanced instruments and software for research applications of mIF. The joint solution will integrate both companies' existing offerings to enhance the value for the users and address multiple market segments, including:

Research: Providing advanced mIF tools for scientific exploration; Diagnostic (Dx) and Companion Diagnostic (CDx) Development: Empowering personalized medicine initiatives; and Clinical Routine: Offering reliable, AI-powered tools for everyday pathological assessments.

“Mindpeak’s established product portfolio of clinical AI algorithms, which currently supports pathologists in assessing immunohistochemistry (IHC), hematoxylin and eosin (H&E) stained slides, will be extended to mIF in this promising partnership,” said Felix Faber, CEO at Mindpeak. “We are thrilled to combine our expertise in AI pathology with ZEISS’s instrumentation to create a streamlined workflow from slide to report for our customers.”

“At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Mindpeak marks a significant milestone in advancing workflows for translational and clinical pathology,” said Michael Albiez, Head of ZEISS Research Microscopy Solutions. “Together, we are introducing an integrated solution that streamlines mIF workflows and improves reproducibility to meet the evolving needs of both translational research and clinical settings. By combining ZEISS' imaging expertise with Mindpeak's AI-driven analytics, we aim to enable researchers and clinicians to gain deeper insights with greater efficiency and precision.”

The partnership combines complementary competencies and expands both companies’ reach in the growing mIF market. ZEISS and Mindpeak will make their first joint appearance at the ESSB (European Society for Molecular Biomarkers) Conference in Berlin, December 12-13, 2024, showcasing the new mIF solution to pathologists and researchers. Additional details will be shared as the development of the platform progresses.

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care. For more information, visit mindpeak.ai, X, and LinkedIn.